Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group
about
Advances in immunotherapy for melanomaImproving outcomes in patients with melanoma: strategies to ensure an early diagnosis.Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease AfterAdjuvant treatment of melanomaUpdate on use of aldesleukin for treatment of high-risk metastatic melanoma.Changes in peripheral blood lymphocytes in polycythemia vera and essential thrombocythemia patients treated with pegylated-interferon alpha and correlation with JAK2V617F allelic burden.Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse modelTumor-targeting Salmonella typhimurium A1-R combined with temozolomide regresses malignant melanoma with a BRAF-V600E mutation in a patient-derived orthotopic xenograft (PDOX) model.Adjuvant therapy for high-risk melanomaImmunotherapy of melanoma: efficacy and mode of action.Targeting mitosis-regulating genes in cisplatin-sensitive and -resistant melanoma cells: A live-cell RNAi screen displays differential nucleus-derived phenotypes.A long-term survivor with esophageal melanoma and pulmonary metastasis after single-stage esophagectomy and lobectomy: Case report and literature review.An unusual case of desmoplastic malignant melanoma.Second European post-chicago melanoma meeting 2012.Tumor-Targeting Salmonella typhimurium A1-R Sensitizes Melanoma With a BRAF-V600E Mutation to Vemurafenib in a Patient-Derived Orthotopic Xenograft (PDOX) Nude Mouse Model.Salmonella typhimurium A1-R targeting of a chemotherapy-resistant BRAF-V600E melanoma in a patient-derived orthotopic xenograft (PDOX) model is enhanced in combination with either vemurafenib or temozolomide.Combination treatment with recombinant methioninase enables temozolomide to arrest a BRAF V600E melanoma in a patient-derived orthotopic xenograft (PDOX) mouse model.Targeting methionine with oral recombinant methioninase (o-rMETase) arrests a patient-derived orthotopic xenograft (PDOX) model of BRAF-V600E mutant melanoma: implications for chronic clinical cancer therapy and prevention.High frequency of brain metastases after adjuvant therapy for high-risk melanoma.Connexin 43 upregulation by dioscin inhibits melanoma progression via suppressing malignancy and inducing M1 polarization.Recombinant methioninase (rMETase) is an effective therapeutic for BRAF-V600E-negative as well as -positive melanoma in patient-derived orthotopic xenograft (PDOX) mouse models.Adjuvant Therapy for Melanoma.Immunotherapy in Melanoma, Gastrointestinal (GI), and Pulmonary Malignancies
P2860
Q26768558-9A609FC3-88D3-49A8-9090-0385135B8C37Q36277934-24E5ABC6-44C9-4689-8C4F-7CED63A000D4Q36346631-8D5C1039-4260-4D2B-B055-C630A6819526Q36656595-AF829670-7910-466C-94BD-820B33A0561CQ37031696-CD633F49-7BFB-418E-B243-77B6A570989AQ37286731-E4B829BD-259D-445C-BCFD-93180BC4AF8AQ37687695-4BDB2444-D0BD-41ED-B279-5F65BDF365A4Q37699156-10628D72-1B05-45D5-929A-3E2FC4E910FFQ38555842-E6432A0F-75EE-42EE-9FF9-E9017D795B02Q38682131-44CD9564-9C4E-41CD-B3DC-B83EB460BDCBQ38886428-4B668E27-F2FD-4C55-8D5E-07D5A6EDD6B9Q39326649-46AACC3D-19CA-4F04-8E8A-9F1223BBF098Q39997210-17B6582C-4D0B-4A47-BE08-23FF346B880FQ42015329-6985D7FB-5FB8-4DD8-A01B-4917BFBBB525Q44538901-734815FB-8C1B-4F20-9DE8-500C76D83DFAQ46020823-9DB19228-72A5-45CF-87CE-E7C9CCAC4319Q46198099-B6121259-66D9-4EF1-B6EB-7FDAA2F9D561Q46341637-AC70B73B-B2A7-4E9D-928B-DA5C8679199DQ46458615-1B136F29-E7DC-4283-8001-8CEF589EE4ECQ48177601-DD576571-A81E-467D-9474-5748BE44BAD1Q49185022-35DB5DBB-8DCA-4787-8C82-3593DC1BF1D2Q51052594-1112A677-B85F-48A6-94CB-3CFED9BA5E8EQ56896166-5E9A4FE0-9954-43B4-BE4C-C03710C0F4B7
P2860
Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Southwest Oncology Group S0008 ...... y of cancer and leukemia Group
@ast
Southwest Oncology Group S0008 ...... y of cancer and leukemia Group
@en
Southwest Oncology Group S0008 ...... y of cancer and leukemia Group
@nl
type
label
Southwest Oncology Group S0008 ...... y of cancer and leukemia Group
@ast
Southwest Oncology Group S0008 ...... y of cancer and leukemia Group
@en
Southwest Oncology Group S0008 ...... y of cancer and leukemia Group
@nl
prefLabel
Southwest Oncology Group S0008 ...... y of cancer and leukemia Group
@ast
Southwest Oncology Group S0008 ...... y of cancer and leukemia Group
@en
Southwest Oncology Group S0008 ...... y of cancer and leukemia Group
@nl
P2093
P2860
P356
P1476
Southwest Oncology Group S0008 ...... y of cancer and leukemia Group
@en
P2093
Alberto S Pappo
Antoni Ribas
Bruce G Redman
Frank G Haluska
James Moon
Jeffrey A Sosman
John A Thompson
John M Kirkwood
John T Vetto
Lawrence E Flaherty
P2860
P304
P356
10.1200/JCO.2013.53.1590
P407
P50
P577
2014-10-20T00:00:00Z